Journal article
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
Biology of blood and marrow transplantation, Vol.24(6), pp.1163-1171
06/2018
DOI: 10.1016/j.bbmt.2017.12.771
PMCID: PMC5993598
PMID: 29242111
Abstract
•Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS).•FL patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%).
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.
Details
- Title: Subtitle
- Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
- Creators
- Carla Casulo - University of RochesterJonathan W. Friedberg - University of RochesterKwang W. Ahn - Medical College of WisconsinChristopher Flowers - Emory UniversityAlyssa DiGilio - Medical College of WisconsinSonali M. Smith - University of ChicagoSairah Ahmed - The University of Texas MD Anderson Cancer CenterDavid Inwards - Mayo Clinic in FloridaMahmoud Aljurf - King Faisal Specialist Hospital & Research CentreAndy I. Chen - Oregon Health & Science UniversityHannah Choe - Cornell UniversityJonathon Cohen - Emory UniversityEdward Copelan - Carolinas Healthcare SystemUmar Farooq - University of IowaTimothy S. Fenske - Medical College of WisconsinCesar Freytes - CHRISTUS Transplant InstituteSameh Gaballa - Thomas Jefferson University HospitalSiddhartha Ganguly - University of KansasYogesh Jethava - University of Arkansas for Medical SciencesRammurti T. Kamble - Baylor College of MedicineVaishalee P. Kenkre - University of Wisconsin–MadisonHillard Lazarus - University Hospitals Seidman Cancer CenterAleksandr Lazaryan - University of MinnesotaRichard F. Olsson - Uppsala UniversityAndrew R. Rezvani - Stanford Health CareDavid Rizzieri - Duke UniversitySachiko Seo - National Cancer Center Hospital EastGunjan L. Shah - Memorial Sloan Kettering Cancer CenterNina Shah - The University of Texas MD Anderson Cancer CenterMelham Solh - Northside HospitalAnna Sureda - Institut Català d'OncologiaBasem William - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteAaron Cumpston - West Virginia University HospitalsAndrew D. Zelenetz - Memorial Sloan Kettering Cancer CenterBrian K. Link - Medical College of WisconsinMehdi Hamadani - Medical College of Wisconsin
- Resource Type
- Journal article
- Publication Details
- Biology of blood and marrow transplantation, Vol.24(6), pp.1163-1171
- DOI
- 10.1016/j.bbmt.2017.12.771
- PMID
- 29242111
- PMCID
- PMC5993598
- NLM abbreviation
- Biol Blood Marrow Transplant
- ISSN
- 1083-8791
- eISSN
- 1523-6536
- Publisher
- Elsevier Inc
- Grant note
- name: Public Health Service, award: U24-CA076518; DOI: 10.13039/100000054, name: National Cancer Institute; DOI: 10.13039/100000050, name: National Heart, Lung, and Blood Institute, ; DOI: 10.13039/100000060, name: National Institute of Allergy and Infectious Diseases, award: 5U10HL069294, HHSH250201200016C; DOI: 10.13039/100000102, name: Health Resources and Services Administration, award: N00014-13-1-0039, N00014-14-1-0028); DOI: 10.13039/100000006, name: Office of Naval Research; DOI: 10.13039/100010535, name: Actinium Pharmaceuticals; DOI: 10.13039/100007136, name: Karyopharm Therapeutics; DOI: 10.13039/100002429, name: Amgen, Inc.; DOI: 10.13039/100008980, name: Medical College of Wisconsin; DOI: 10.13039/100006413, name: Ariad; DOI: 10.13039/100001738, name: Be The Match Foundation; DOI: 10.13039/100007501, name: Blue Cross and Blue Shield Association; DOI: 10.13039/100006436, name: Celgene Corporation; DOI: 10.13039/100016875, name: Chimerix, Inc.; DOI: 10.13039/100005895, name: Fred Hutchinson Cancer Research Center; name: Fresenius-Biotech North America, Inc.; name: Gamida Cell Teva Joint Venture Ltd.; DOI: 10.13039/100004328, name: Genentech, Inc.; name: Gentium SpA; DOI: 10.13039/100004329, name: Genzyme Corporation; DOI: 10.13039/100004330, name: GlaxoSmithKline; DOI: 10.13039/100005622, name: Health Research, Inc.; DOI: 10.13039/100001320, name: Roswell Park Cancer Institute; name: HistoGenetics, Inc.; name: Incyte Corporation; name: Jeff Gordon Children's Foundation; DOI: 10.13039/501100004072, name: Kiadis Pharma; DOI: 10.13039/100005189, name: Leukemia & Lymphoma Society; DOI: 10.13039/501100014841, name: Medac GmbH; DOI: 10.13039/100008980, name: Medical College of Wisconsin; DOI: 10.13039/100004334, name: Merck & Co., Inc.; name: Millennium: The Takeda Oncology Co.; name: Milliman USA, Inc.; DOI: 10.13039/501100004176, name: Miltenyi Biotec; name: National Marrow Donor Program; DOI: 10.13039/100007072, name: Onyx Pharmaceuticals; name: Optum Healthcare Solutions, Inc.; DOI: 10.13039/100007075, name: Osiris Therapeutics; DOI: 10.13039/100009155, name: Otsuka America Pharmaceutical, Inc.; name: Perkin Elmer, Inc.; name: Remedy Informatics; DOI: 10.13039/100004339, name: Sanofi US; DOI: 10.13039/100010293, name: Seattle Genetics; DOI: 10.13039/100009996, name: Sigma-Tau Pharmaceuticals; name: Soligenix, Inc.; DOI: 10.13039/100006058, name: St. Baldrick's Foundation; DOI: 10.13039/100008761, name: StemCyte, A Global Cord Blood Therapeutics Co.; name: Stemsoft Software, Inc.; DOI: 10.13039/501100012112, name: Swedish Orphan Biovitrum; DOI: 10.13039/100007127, name: Tarix Pharmaceuticals; name: TerumoBCT; name: Teva Neuroscience, Inc.; DOI: 10.13039/100007163, name: Therakos, Inc.; DOI: 10.13039/100007249, name: University of Minnesota; DOI: 10.13039/100007747, name: University of Utah; DOI: 10.13039/100004382, name: WellPoint, Inc.
- Language
- English
- Date published
- 06/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359910102771
Metrics
24 Record Views